EHA 2022 | Key updates in CAR-T therapy from EHA 2022
Christian Chabannon
• 11 Jun 2022
Christian Chabannon, MD, PhD, Institut Paoli-Calmettes, Marseille, France, shares the most important updates in CAR-T therapy that were shared at the session on immune therapies for hematologic disorders that took place at this year’s EHA congress. The experts discussed technological developments in CAR-T therapy, as well as ongoing trials evaluating novel CAR-T constructs, and the management of CAR-T therapy-related toxicities. In addition, Prof. Chabannon comments on the practice-changing results of the ZUMA-7 (NCT03391466) and TRANSFORM (NCT03575351) trials. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
